Advanced search
Publication Cover
Journal of Medical Economics Volume 27, 2024 - Issue 1
Submit an article Journal homepage
333
Views
0
CrossRef citations to date
0
Altmetric
Migraine

Placebo responses vary by route of administration in migraine prevention trials. What does this mean?

Christina I. Deligiannia Neurology Department, Athens Naval Hospital, Athens, Greece;b 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian Universtiy of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0002-6208-1059View further author information
ORCID Icon,
Paolo Martellettic School of Health Sciences, Unitelma Sapienza University of Rome, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-6556-4128View further author information
ORCID Icon &
Dimos D. Mitsikostasb 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian Universtiy of Athens, Athens, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4691-3388View further author information
ORCID Icon
Pages 442-444 | Received 01 Nov 2023, Accepted 23 Feb 2024, Published online: 12 Mar 2024

References

  • Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876. doi: 10.1056/NEJMra1915327.
  • Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026–1044. doi: 10.1177/0333102420941839.
  • Linde M, May A, Limmroth V, et al. Ethical aspects of placebo in migraine research. Cephalalgia. 2003;23(7):491–495. Available from: https://pubmed.ncbi.nlm.nih.gov/12950373/
  • Skierka AS, Michels KB. Ethical principles and placebo-controlled trials - Interpretation and implementation of the Declaration of Helsinki’s placebo paragraph in medical research. BMC Med Ethics. 2018;19(1):24. doi: 10.1186/s12910-018-0262-9.
  • Mitsikostas DD, Blease C, Carlino E, et al. European Headache Federation recommendations for placebo and nocebo terminology. J Headache Pain. 2020;21(1):117. doi: 10.1186/s10194-020-01178-3.
  • Tepper SJ, Cirillo J, Kim E, et al. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023;24(1):54. doi: 10.1186/s10194-023-01587-0.
  • Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31(5):550–561. doi: 10.1177/0333102410391485.
  • Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurother. 2010;10(3):413–419. doi: 10.1586/ern.10.8.
  • Macedo A, Baños JE, Farré M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain. 2008;12(1):68–75. doi: 10.1016/j.ejpain.2007.03.002.
  • Kokoti L, Drellia K, Papadopoulos D, et al. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. J Neurol. 2020;267(4):1158–1170. doi: 10.1007/s00415-019-09673-7.
  • Regnier SA, Lee XY. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention. J Med Econ. 2023;26(1):1072–1080. doi: 10.1080/13696998.2023.2248842.
  • Mitsikostas DD, Goodin DS. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2017;18:109–116. doi: 10.1016/j.msard.2017.08.003.
  • Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254. doi: 10.1177/0333102420905132.
  • Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008. doi: 10.1001/jama.2018.4853.
  • Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022;23(1):67. doi: 10.1186/s10194-022-01431-x.
  • Mitsikostas DD, Alexoudi A, Arvaniti C, et al. Hellenic Headache Society recommendations for the use of monoclonal antibodies targeting the calcitonin Gene-Related peptide pathway for the prevention of migraine and cluster headache—2023 update. SN Compr Clin Med. 2023;5(1):118. doi: 10.1007/s42399-023-01452-w.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.